Human Papillomavirus (HPV) Vaccine Global Market Report 2024

The human papillomavirus (hpv) vaccine market size has grown rapidly in recent years. It will grow from $5.12 billion in 2023 to $5.87 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth observed in the historical period can be attributed to factors such as the initial development of the HPV vaccine, the establishment of medical guidelines and recommendations, government-sponsored vaccination campaigns, educational initiatives focused on HPV risks, and improvements in vaccine accessibility.

The human papillomavirus (hpv) vaccine market size is expected to see rapid growth in the next few years. It will grow to $9.61 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The anticipated growth in the forecast period can be attributed to efforts in health equity and vaccine equity, inclusion in travel health recommendations, targeted vaccination strategies, investments from the pharmaceutical industry, and the adoption of telemedicine and remote vaccination. Major trends expected in the forecast period include innovation in adjuvant technology, the role of HPV vaccination in LGBTQ+ health, a focus on immunocompromised populations, integration with cancer screening programs, and the implementation of community-based education programs.

The human papillomavirus (HPV) vaccine market is poised for growth, driven by the increased prevalence of HPV-related diseases. These viral infections often manifest as warts on the skin or mucous membranes, and the HPV vaccine specifically targets these subtypes, effectively mitigating the risk of infection and associated diseases. For instance, recent data from the National Cancer Institute indicates an anticipated diagnosis of approximately 13,960 cases of aggressive cervical cancer in American women, with an expected 4,310 fatalities in 2023. The alarming prevalence of HPV-related diseases, such as cervical cancer, underscores the imperative role of the HPV vaccine in curbing these health risks.

Increasing global immunization coverage is poised to drive growth in the human papillomavirus (HPV) vaccine market. Immunization coverage denotes the percentage of a population that has received specific vaccines or a recommended set of vaccines within a defined timeframe. The expansion of immunization coverage fuels heightened demand for HPV vaccines, which provide protection against virus strains incorporated into routine vaccination programs, effectively addressing multiple disease threats with a single shot. For example, as of July 2023, data from the World Health Organization (WHO), an international public health organization based in Switzerland, revealed positive trends. In 2022, the number of zero-dose children, indicating those who did not receive any vaccinations, decreased from 18.1 million in 2021 to 14.3 million. Additionally, global coverage for the initial dose of the HPV vaccine in girls witnessed an increase from 16% in 2021 to 21% in 2022. These developments underscore the positive impact of rising global immunization coverage on the growth trajectory of the HPV vaccine market in the foreseeable future.

A key trend in the human papillomavirus (HPV) vaccine market is the focus on product innovation, with companies adopting new technologies to maintain their market standing. Notably, the Serum Institute of India introduced CERVAVAC, the first quadrivalent HPV vaccine developed entirely by Indian scientists. This innovative vaccine, aimed at immunizing girls aged 9 to 14 against cervical cancer, signifies a noteworthy advancement in the field and addresses the need for affordable and cost-effective solutions.

Major companies in the human papillomavirus (HPV) vaccine market are prioritizing the development of innovative products, including the introduction of 9-valent vaccines to drive market revenues. The 9-valent vaccine provides protection against nine types of HPV, offering a comprehensive approach to preventing various HPV-related illnesses. For instance, MSD Pharmaceuticals Pvt. Ltd., a biopharmaceutical company, launched Gardasil 9, the first gender-neutral HPV vaccine, designed to protect against multiple HPV types linked to genital warts and cervical cancer. This gender-neutral vaccine aims to reduce the incidence of HPV-related illnesses in both Indian girls and boys aged 9 to 26.

In January 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, merged with the Serum Institute of India. This collaboration not only ensures a committed revenue stream and associated margins for Biocon Biologics Ltd. but also facilitates the development of antibodies targeting infectious diseases, including HPV. The Serum Institute of India, known for manufacturing qHPV vaccines and immuno-biologicals, reinforces the collective efforts to combat HPV-related health challenges.

Major companies operating in the human papillomavirus (hpv) vaccine market report are Johnson & Johnson Co, Merck & Co Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Pharma Ltd., Astellas Pharma Inc., CSL Limited, UCB SA, Serum Institute of India Pvt Ltd., Beijing Wantai Biological Pharmacy Enterprise Co Ltd., Emergent BioSolutions Inc., Bharat Biotech International Ltd., Walvax Biotechnology Co Ltd., Bavarian Nordic AS, Biofarma Co, Vaccitech PLC, Inovio Pharmaceuticals Inc., R-Pharm LLC, PathoVax LLC.

North America was the largest region in the human papillomavirus (HPV) vaccine market in 2023. The regions covered in the human papillomavirus (hpv) vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human papillomavirus (hpv) vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of Human Papillomavirus (HPV) vaccines are tetravalent, nonavalent, and bivalent. Tetravalent vaccines activate the body's defenses against four distinct antigens, providing an immunological response against four different viruses or microbes. These vaccines target disease indications such as cervical cancer, anal cancer, vulvar and vaginal cancer, penile cancer, oropharyngeal cancer, and others. Distribution channels include hospitals, retail pharmacies, government suppliers, and others. The industry verticals involved encompass public and private alliances, government entities, physicians, and others.

The human papillomavirus (HPV) vaccine market research report is one of a series of new reports that provides human papillomavirus (HPV) vaccine market statistics, including human papillomavirus (HPV) vaccine industry global market size, regional shares, competitors with a human papillomavirus (HPV) vaccine market share, detailed human papillomavirus (HPV) vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the human papillomavirus (HPV) vaccine industry. This human papillomavirus (HPV) vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human papillomavirus (HPV) vaccine market consists of sales of gardasil 9, gardasil, and cervarix. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.